The present invention provides methods for use in protein purification. The disclosed methods help avoid precipitation events and can be used to improve the performance and/or efficiency of protein purification protocols. The methods may be used to improve or prepare solutions for use in protein purification and/or protein extraction processes. One particular application of the disclosed method is in affinity chromatography where it may be applied to the preparation of load solutions.
C07D 215/227 - Oxygen atoms attached in position 2 or 4 only one oxygen atom which is attached in position 2
C07D 215/52 - Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 4 with aryl radicals attached in position 2
C07D 401/04 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring- member bond
C07D 401/12 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
C07D 413/04 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring- member bond
Described are extended release drug-loaded microparticles, pharmaceutical compositions comprising them, methods of making them, and therapeutic methods using them.
A61K 47/34 - Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
A61K 47/14 - Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
A61K 47/44 - Oils, fats or waxes according to two or more groups of Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
The present disclosure provides methods of detection and diagnosis of ectopic endometriosis. The disclosure further provides compositions, medicaments and methods for treating or preventing ectopic endometriosis.
The subject invention provides a pharmaceutical composition comprising: (i) at least one bacteriophage strain(s) capable of producing a lytic infection in an adherent-invasive Escherichia coli strain; and (ii) a pharmaceutically acceptable carrier; for the treatment of inflammatory bowel disease.
The subject invention provides a pharmaceutical composition comprising: (i) at least one bacteriophage strain(s) capable of producing a lytic infection in an adherent-invasive Escherichia coli strain; and (ii) a pharmaceutically acceptable carrier; for the treatment of inflammatory bowel disease.
The subject invention further provides a method of treating inflammatory bowel disease comprising administering to a subject in need thereof at least one bacteriophage strain capable of producing a lytic infection in an adherent-invasive Escherichia coli strain thereby treating the subject.
The subject invention provides a pharmaceutical composition comprising: (i) at least one bacteriophage strain(s) capable of producing a lytic infection in an adherent-invasive Escherichia coli strain; and (ii) a pharmaceutically acceptable carrier; for the treatment of inflammatory bowel disease.
The subject invention further provides a method of treating inflammatory bowel disease comprising administering to a subject in need thereof at least one bacteriophage strain capable of producing a lytic infection in an adherent-invasive Escherichia coli strain thereby treating the subject.
The subject invention also provides new bacteriophage strains.
The present disclosure relates to methods for preparing peptide salts, in particular pharmaceutically acceptable peptide salts, such as salts of atosiban (e.g. atosiban pamoate). The present disclosure further extends to the preparation of particles of such salts, such as via a spray drying process.
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Pharmaceutical and biopharmaceutical products, preparations and agents; pharmaceutical and biopharmaceutical products, preparations and agents used for the treatment of diseases and conditions in the area orthopaedics
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Pharmaceutical and biopharmaceutical products, preparations and agents; pharmaceutical and biopharmaceutical products, preparations and agents used for the treatment of diseases and conditions in the area orthopaedics
11.
METHODS OF TREATING PROSTATE CANCER WITH GnRH ANTAGONIST
The invention provides methods and dosing regimens for safely and effectively treating androgen-dependent prostate cancer with a gonadotrophin releasing hormone (GnRH) antagonist without causing a testosterone spike and/or other side effect of GnRH agonist therapy such as a urinary tract infection, or an arthralgia-related or cardiovascular side effect.
Disclosed herein are small molecule follicle-stimulating hormone (FSH) receptor modulators, methods of making them, and therapeutic methods using them.
A61P 15/08 - Drugs for genital or sexual disordersContraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
Described herein are bacteriophages that infect and lyse Vancomycin-Resistant Enterococci (VRE). The bacteriophages are useful, for example, for the prophylactic or therapeutic treatment of subjects infected with Enterococci, including VRE, or who are at risk of infection by Enterococci, including VRE, and for other uses described herein.
05 - Pharmaceutical, veterinary and sanitary products
10 - Medical apparatus and instruments
41 - Education, entertainment, sporting and cultural services
44 - Medical, veterinary, hygienic and cosmetic services; agriculture, horticulture and forestry services
Goods & Services
Pharmaceutical preparations; dietetic food and substances
adapted for medical use; dietary supplements for humans;
medical preparations. Surgical and medical apparatus and instruments. Education; arranging, organizing and conducting of
educational and scientific events and forums; publication of
printed matter, including in electronic form (other than for
advertising purposes). Medical services; human healthcare services; medical
information services.
15.
STEREOSELECTIVE SYNTHESIS OF INTERMEDIATES AND SYNTHESIS OF QUINAGOLIDS
Disclosed is a method for preparing compounds with improved stereoselectivities. The described compounds are useful intermediates and may find particular application in the synthesis of compounds containing an octahydrobenzoquinoline moiety (e.g. an octahydrobenzo[g]quinoline moiety), such as quinagolide and its derivatives. Also disclosed is a method for stereoselectively (e.g. enantioselectively) preparing an intermediate used in the existing manufacturing process for the synthesis of quinagolide this intermediate also finding utility in the synthesis of other compounds containing an octahydrobenzo[g]quinoline moiety, in particular those having a substituent at the 3- position on the octahydrobenzo[g]quinoline.
C07C 229/34 - Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton containing six-membered aromatic rings
C07C 227/18 - Preparation of compounds containing amino and carboxyl groups bound to the same carbon skeleton from compounds containing already amino and carboxyl groups or derivatives thereof by reactions involving amino or carboxyl groups, e.g. hydrolysis of esters or amides, by formation of halides, salts or esters
C07C 227/32 - Preparation of optical isomers by stereospecific synthesis
A solid pharmaceutical formulation comprising a mixture of (1) lyophilized granules comprising sildenafil or a pharmaceutically acceptable salt thereof as active ingredient and (2) a non-lyophilized composition, wherein the formulation comprises 35% to 50% by weight of the lyophilized granules (1) and dissolves in the oral cavity and the non-lyophilized composition (2) is a solid blend composition comprising flow enhancing agents, a package containing the formulation, and a process for the manufacture of the formulation.
05 - Pharmaceutical, veterinary and sanitary products
10 - Medical apparatus and instruments
44 - Medical, veterinary, hygienic and cosmetic services; agriculture, horticulture and forestry services
Goods & Services
Pharmaceutical preparations; dietetic food and substances adapted for medical use; dietary supplements for humans; medical preparations and articles Surgical and medical apparatus and instruments; parts and fittings of all the aforesaid goods included in this class Medical services; human healthcare services
Described herein are aqueous pharmaceutical compositions comprising lidocaine, hyaluronic acid, and chondroitin sulphate (or a pharmaceutically acceptable salts of any thereof) and water, as well as methods of making such aqueous pharmaceutical compositions, and therapeutic methods using them.
A61K 31/167 - Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen atom of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
Described herein are processes for preparing enzalutamide nanocrystals, compositions and pharmaceutical compositions comprising them, and therapeutic methods using them.
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Implant material being synthetic peptides for inducing and augmenting bone formation and repair; synthetic growth-factor peptides applied to orthopedic medical devices and materials for use with invasive and other medical procedures for inducing and augmenting bone formation and repair
05 - Pharmaceutical, veterinary and sanitary products
10 - Medical apparatus and instruments
41 - Education, entertainment, sporting and cultural services
44 - Medical, veterinary, hygienic and cosmetic services; agriculture, horticulture and forestry services
Goods & Services
(1) Pharmaceutical preparations; dietetic food and substances adapted for medical use; dietary supplements for humans; medical preparations.
(2) Surgical and medical apparatus and instruments. (1) Education; arranging, organizing and conducting of educational and scientific events and forums; publication of printed matter, including in electronic form (other than for advertising purposes).
(2) Medical services; human healthcare services; medical information services.
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Pharmaceutical products and preparations for treating blood disorders and conditions; pharmaceutical products and preparations for treating hormonal disorders and conditions; pharmaceutical products and preparations for treating rare diseases; pharmaceutical products and preparations for treating urological disorders and conditions; pharmaceutical products and preparations for treating diabetes insipidus
This disclosure relates to a method of treating Prader-Willi Syndrome. The method includes administering to a patient in need thereof an effective amount of a composition containing a selective oxytocin receptor agonist or a pharmaceutically acceptable salt thereof.
A61P 15/08 - Drugs for genital or sexual disordersContraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
G01N 33/68 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving proteins, peptides or amino acids
A61P 15/08 - Drugs for genital or sexual disordersContraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Pharmaceutical products and preparations for the treatment of diseases and conditions in the areas of reproductive health, fertility, gynecology and obstetrics; vaginal suppositories for delivery of pharmaceuticals to the body
The invention provides a pharmaceutical composition comprising activated carbon particles, for oral administration. The pharmaceutical composition may be for (use in) the treatment of gastrointestinal fistula.
42 - Scientific, technological and industrial services, research and design
Goods & Services
Medical research and development for others of synthetic bioactive peptides, custom compositions and coatings for medical device implants and for use in surgical procedures
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Pharmaceutical products and preparations for the prevention or treatment of urological diseases, disorders and conditions, diabetes insipidus, constipation, chronic bowel disease, arthritis, autoimmune diseases and disorders, cancer, reproductive health diseases, disorders and conditions, pain, hormonal diseases, disorders and conditions and endocrinological diseases, disorders and conditions
The present invention relates to improved assisted reproductive technology using highly purified menotropin (HP-hMG) to stimulate follicle development in controlled ovarian stimulation, particularly in women at risk of a high ovarian response to controlled ovarian stimulation.
A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
A61P 15/08 - Drugs for genital or sexual disordersContraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
33.
COMPOSITIONS AND METHODS FOR INTRAUTERINE INSEMINATION (IUI)
A61P 15/08 - Drugs for genital or sexual disordersContraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
Methods, uses and compositions including rFSH including α2,3- and α2,6-sialylation for use in the treatment of infertility in a male patient are described.
The present invention pertains in general to the field of the stabilization of gonadotropin formulations, in particular liquid formulations of gonadotropins. The stabilization is achieved by a particular combination of excipients, preferably arginine and methionine. In a preferred embodiment, the formulation does not comprise a buffer.
A61P 15/08 - Drugs for genital or sexual disordersContraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
A61K 47/26 - Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharidesDerivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
A free-flowing solid pharmaceutical formulation comprising one or more active ingredients and a blend comprising sorbitol and liquid paraffin, a package containing the formulation, a process for the manufacture of the formulation and the use of the blend in the formulation.
A61K 9/19 - Particulate form, e.g. powders lyophilised
A61K 31/4545 - Non-condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
A61K 31/4725 - Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
A61K 31/519 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
Methods, uses and products including a recombinant human follicle stimulating hormone (rFSH) including α2,3- and α2,6-sialylation and menotropin (human menopausal gonadotropin or hMG) for use in the treatment of infertility in a patient of age ≥35 are described.
A61P 15/08 - Drugs for genital or sexual disordersContraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
41.
HP-HMG FOR USE IN THE TREATMENT OF INFERTILITY IN A PATIENT WITH POLYCYSTIC OVARY SYNDROME
Described are assisted reproductive technology compositions and methods using highly purified menotropin (HP-hMG) to stimulate follicle development, particularly in women who have been diagnosed with oligoovulation and/or PCOS and who are predicted to have a high ovarian response to controlled ovarian stimulation.
A61P 15/08 - Drugs for genital or sexual disordersContraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
The invention provides a polypeptide dimer comprising two gp130-Fc fusion peptides for use in the treatment of ASCVD in human patients, preferably of high-risk ASCVD in human patients, more preferably of very-high-risk ASCVD in human patients.
C07K 14/715 - ReceptorsCell surface antigensCell surface determinants for cytokinesReceptorsCell surface antigensCell surface determinants for lymphokinesReceptorsCell surface antigensCell surface determinants for interferons
A61P 9/10 - Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Pharmaceutical products and preparations; gene-based
pharmaceutical products and preparations; pharmaceutical
products and preparations against cancer; pharmaceutical
products and preparations against bladder diseases; sanitary
preparations for medical purposes.
44.
COMPOSITION COMPRISING HP-HMG FOR USE IN TREATING INFERTILITY
The present invention relates to improved assisted reproductive technology for women predicted to have a high ovarian response to controlled ovarian stimulation that comprise targeting a threshold serum hCG level by the final day of stimulation.
A61B 17/435 - Gynaecological or obstetrical instruments or methods for reproduction or fertilisation for embryo transplantation
A61P 15/08 - Drugs for genital or sexual disordersContraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
Compositions and methods for treating patients are disclosed. An example composition may include a vaginal microbiota composition. The vaginal microbiota composition may include a mixture of bacteria. The mixture of bacteria may include Lactobacillus crispatus, Lactobacillus gasseri, Lactobacillus jensenii, and Lactobacillus rhamnosus.
The present invention provides methods for use in protein purification. The disclosed methods help avoid precipitation events and can be used to improve the performance and/or efficiency of protein purification protocols. The methods may be used to improve or prepare solutions for use in protein purification and/or protein extraction processes. One particular application of the disclosed method is in affinity chromatography where it may be applied to the preparation of load solutions.
The present invention provides methods for use in protein purification. The disclosed methods help avoid precipitation events and can be used to improve the performance and/or efficiency of protein purification protocols. The methods may be used to improve or prepare solutions for use in protein purification and/or protein extraction processes. One particular application of the disclosed method is in affinity chromatography where it may be applied to the preparation of load solutions.
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
(1) Pharmaceutical products and preparations; gene-based pharmaceutical products and preparations; pharmaceutical products and preparations against cancer; pharmaceutical products and preparations against bladder diseases; sanitary preparations for medical purposes.
Described herein are pharmaceutical compositions comprising diclofenac and therapeutic methods for using them effective with once daily administration.
A61K 31/196 - Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
A61K 9/00 - Medicinal preparations characterised by special physical form
The present invention relates to monolithic intravaginal rings comprising progesterone, methods of making, and uses thereof. The intravaginal rings comprise progesterone, a polysiloxane elastomer, and a pharmaceutically acceptable hydrocarbon or glycerol esters of a fatty acid.
A61K 31/57 - Compounds containing cyclopenta[a]hydrophenanthrene ring systemsDerivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
A61F 6/08 - Pessaries, i.e. devices worn in the vagina to support the uterus, remedy a malposition or prevent conception
A61K 9/00 - Medicinal preparations characterised by special physical form
A61K 47/34 - Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
A61K 47/44 - Oils, fats or waxes according to two or more groups of Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
B29C 45/00 - Injection moulding, i.e. forcing the required volume of moulding material through a nozzle into a closed mouldApparatus therefor
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Pharmaceutical and biopharmaceutical products and preparations used for the treatment of microbiota dysfunction diseases and disorders; drug delivery devices sold filled with pharmaceutical preparations to treat gut microbiome-related disorders; drug delivery devices sold filled with pharmaceutical preparations to treat gut microbiome-related disorders in the nature of a kit comprising a prefilled suspension bag and administration tube set
A61K 47/20 - Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
A61K 47/26 - Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharidesDerivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Pharmaceutical products and preparations to treat cancer and bladder diseases; gene-based pharmaceutical products and preparations to treat cancer and bladder diseases
A61K 47/14 - Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
A61K 47/22 - Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
A61K 47/44 - Oils, fats or waxes according to two or more groups of Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
A61K 47/14 - Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
A61K 47/22 - Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
A61K 47/44 - Oils, fats or waxes according to two or more groups of Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
Synthetic growth-factor analog peptide products, namely, peptide coated bone graft substitutes for filling voids and gaps in bone including those of the vertebral column, for use with invasive and other medical procedures
58.
ADRENOCORTICOTROPIC HORMONE PEPTIDE COMPOSITIONS AND METHODS OF USE
Described herein are aqueous pharmaceutical compositions comprising peptide Met-Glu-His-Phe-Pro-Gly-Pro (SEQ ID NO: 1), or a pharmaceutically acceptable derivative thereof, or a pharmaceutically acceptable salt of any thereof, and therapeutic methods using them.
A61K 47/18 - AminesAmidesUreasQuaternary ammonium compoundsAmino acidsOligopeptides having up to five amino acids
A61K 47/20 - Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
A61K 47/22 - Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
A61K 47/26 - Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharidesDerivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
The present disclosure provides methods of detection and diagnosis of ectopic endometriosis. The disclosure further provides compositions, medicaments and methods for treating or preventing ectopic endometriosis.
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Pharmaceutical and biopharmaceutical products, preparations and agents for the treatment of endocrinological, urological, oncological, reproductive, fertility, gynaecological, obstetrics, gastroenterological, orthopaedics, and immunological diseases and conditions; pharmaceutical and biopharmaceutical agents for the treatment of microbiota dysfunction diseases and disorders
64.
BACTERIOPHAGES AGAINST VANCOMYCIN-RESISTANT ENTEROCOCCI
Described herein are bacteriophages that infect and lyse Vancomycin-Resistant Enterococci (VRE). The bacteriophages are useful, for example, for the prophylactic or therapeutic treatment of subjects infected with Enterococci, including VRE, or who are at risk of infection by Enterococci, including VRE, and for other uses described herein.
Described herein are bacteriophages that infect and lyse Vancomycin-Resistant Enterococci (VRE). The bacteriophages are useful, for example, for the prophylactic or therapeutic treatment of subjects infected with Enterococci, including VRE, or who are at risk of infection by Enterococci, including VRE, and for other uses described herein.
Stable liquid formulations containing picosulfate and magnesium citrate are provided. The formulations are useful to treat constipation or for the clearance of the bowel prior to X-ray examination, endoscopy or surgery.
Promoting public awareness of health issues and dissemination of information promoting public awareness of health issues and healthcare; promoting public awareness of sexual health, reproductive health, fertility planning, and family planning issues and dissemination of information promoting public awareness of sexual health, reproductive health, fertility planning, and family planning issues
70.
BACTERIOPHAGE THERAPY AGAINST ADHERENT-INVASIVE ESCHERICHIA COLI
Described herein are bacteriophages that infect and lyse adherent-invasive Escherichia coli (AIEC). The bacteriophages are useful, for example, for the prophylactic or therapeutic treatment of subjects infected with AIEC or at risk of infection by AIEC, or in the prophylactic or therapeutic treatment of diseases and conditions associated with AIEC, including inflammatory bowel disease (IBD), urinary tract infection (UTI), neonatal meningitis, asthma, chronic obstructive pulmonary disease (COPD), bronchitis, pneumonia, and lung cancer, in a subject in and for other uses described herein.
Escherichia coliEscherichia coli (AIEC). The bacteriophages are useful, for example, for the prophylactic or therapeutic treatment of subjects infected with AIEC or at risk of infection by AIEC, or in the prophylactic or therapeutic treatment of diseases and conditions associated with AIEC, including inflammatory bowel disease (IBD), urinary tract infection (UTI), neonatal meningitis, asthma, chronic obstructive pulmonary disease (COPD), bronchitis, pneumonia, and lung cancer, in a subject in and for other uses described herein.
The present disclosure relates to the use of a novel dosage form of merotocin in improving lactation in a female in need thereof. The disclosure particularly provides the use of a composition suitable for intranasal administration that provides a dose of merotocin greater than 100 μg or substantially about 400 μg to the female. The disclosure encompasses methods of treatment as well as compositions for use in such methods.
05 - Pharmaceutical, veterinary and sanitary products
10 - Medical apparatus and instruments
Goods & Services
Pharmaceutical and biopharmaceutical products and
preparations used for the treatment of diseases and
disorders emanating from microbiota dysfunction. Medical and surgical apparatus and instruments; drug
delivery devices, including medical apparatus and
instruments for administration of pharmaceutical and
biopharmaceutical products and preparations.
A selective IL-6-trans-signalling inhibitor can be used to treat a variety of IL-6-mediated conditions, including inflammatory diseases and cancer. The inhibitor can safely be administered to humans at a variety of doses.
A61K 38/17 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Pharmaceutical products and substances for treating orthopedic diseases and conditions; prescription peptides for treating orthopedic diseases and conditions
77.
Method of treating prostate cancer with GnRH antagonist
The invention provides methods and dosing regimens for safely and effectively treating androgen-dependent prostate cancer with a gonadotrophin releasing hormone (GnRH) antagonist without causing a testosterone spike and/or other side effect of GnRH agonist therapy such as a urinary tract infection, or an arthralgia-related or cardiovascular side effect. The present disclosure also provides for methods for treating prostate cancer in a patient with a history of at least one cardiovascular event, wherein administration of degarelix to the subject decreases the likelihood of developing or experiencing an additional cardiovascular event compared to treatment with a gonadotrophin releasing hormone (GnRH) agonist.
05 - Pharmaceutical, veterinary and sanitary products
10 - Medical apparatus and instruments
Goods & Services
(1) Pharmaceutical and biopharmaceutical products and preparations used for the treatment of diseases and disorders emanating from microbiota dysfunction, namely, diseases and conditions in the areas of endocrinology, urology, oncology, reproductive health, fertility, gynaecology, obstetrics, gastroenterology, orthopaedics, immunology
(2) Surgical instruments; medical tubing; bags and tubing for administering gastrointestinal treatment preparations; medical devices for rectal use in administering pharmaceutical preparations for treating gastrointestinal diseases
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Pharmaceutical and biopharmaceutical products, preparations and agents for the treatment of reproductive, fertility, gynaecological, and obstetric diseases and conditions
The present invention relates to an sgp130 protein, exemplified by olamkicept, for use 5 in treating individuals for inflammatory bowel diseases (IBD). In particular, the invention provides a panel of gene expression biomarkers that predict response in patients with inflammatory bowel disease after a single administration of as sgp130 protein, such as olamkicept.
C12Q 1/6883 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
82.
COMPOSITIONS AND METHODS FOR CONTROLLED OVARIAN STIMULATION
A61P 15/08 - Drugs for genital or sexual disordersContraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
83.
COMPOSITIONS AND METHODS FOR CONTROLLED OVARIAN STIMULATION
A61P 15/08 - Drugs for genital or sexual disordersContraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
84.
Topical pharmaceutical composition for treatment of anal fissures and hemorrhoids
The present invention relates to a topical pharmaceutical composition to be used in the anal region for anal fissures and hemorrhoids, including the postoperative period of hemorrhoidectomy. The pharmaceutical composition comprises an anal dilator, a mucoadhesive polymer and a non-aqueous vehicle. Also described is a method of manufacturing the pharmaceutical composition.
A61K 31/167 - Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen atom of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
A61K 9/00 - Medicinal preparations characterised by special physical form
A61K 31/554 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and at least one sulfur as ring hetero atoms, e.g. clothiapine, diltiazem
A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
85.
Process for the preparation of drug loaded microparticles
e) allowing the spontaneous formation of the nano- and/or microparticles via transfer of organic solvent from the discontinuous organic phase into the continuous aqueous phase directly after the dispersion has been formed.
A selective IL-6-trans-signalling inhibitor can be used to treat a variety of IL-6-mediated conditions, including inflammatory diseases and cancer. The inhibitor can safely be administered to humans at a variety of doses. Moreover, the inhibitor lessens deleterious effects associated with other IL-6 inhibitors such as lowering neutrophil counts, platelet counts and levels of C-reactive protein.
42 - Scientific, technological and industrial services, research and design
Goods & Services
Promoting public awareness of health issues and healthcare Creating and hosting an on-line community for registered users to discuss health and healthcare issues, and share experiences related to health and healthcare; creating and hosting an online community to interact with registered users, and for registered users to interact with each other, through the use of animated graphics, pictures, and videos to promote awareness of health issues
The present disclosure is directed to reducing nocturnal voids by administering a dose of desmopressin over a minimum treatment period compared to before administration, and maintaining or improving the reduction of nocturnal voids over the minimum treatment period.
42 - Scientific, technological and industrial services, research and design
44 - Medical, veterinary, hygienic and cosmetic services; agriculture, horticulture and forestry services
Goods & Services
Medical and clinical research services; scientific research
for medical purposes; providing scientific information in
the field of medical disorders and their treatment;
provision of information and data relating to medical
research and development; pharmaceutical research and
development services; pharmaceutical products development;
research of pharmaceuticals; conducting clinical trials for
pharmaceutical products; information technology services for
the pharmaceutical and healthcare industries; design and
development of software for use in the medical and
pharmaceutical field; Software as a Service [SaaS] services
for use in the medical and pharmaceutical field; Platform as
a Service [PaaS] services for use in the medical and
pharmaceutical field. Human healthcare services; providing information in the
field of human health care; medical services, consultancy,
information and advisory services in the field of
pharmaceutical products and treatments; medical and health
care information services.
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Drug delivery devices sold filled with pharmaceutical preparations to treat gut microbiome-related disorders; drug delivery devices sold filled with pharmaceutical preparations to treat gut microbiome-related disorders in the nature of a kit comprising a prefilled suspension bag and administration tube set
Methods for treating and/or preventing a recurrent Clostridioides difficile infection are disclosed. An example comprises administering one or more doses of an oral microbiota restoration composition to a patient with one or more episodes of a recurrent Clostridioides difficile infection. The oral microbiota restoration composition comprises a lyophilized material comprising fecal microbiota, polyethylene glycol, trehalose, sucrose, and glycerin.
A61K 47/26 - Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharidesDerivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
A61K 47/44 - Oils, fats or waxes according to two or more groups of Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
Disclosed are methods and apparatuses for manufacturing a solid formulation for oral administration, comprising an edible substrate portion on which a composition comprising a first pharmaceutical active ingredient is deposited, and solid formulations made thereby. The methods comprise providing an edible substrate in the form of a film comprising a plurality of portions, spraying a liquid formulation comprising the active ingredient and a solvent onto an edible substrate portion and evaporating the solvent to form a solid composition deposited on the edible substrate portion; measuring the quantity of active ingredient supported by the edible substrate portion and comparing to a predetermined value, and dividing the edible substrate into the plurality of portions.
B41F 17/00 - Printing apparatus or machines of special types or for particular purposes, not otherwise provided for
B65B 9/02 - Enclosing successive articles, or quantities of material, between opposed webs
B65B 35/44 - Arranging and feeding articles in groups by endless belts or chains
B65B 57/14 - Automatic control, checking, warning or safety devices responsive to absence, presence, abnormal feed, or misplacement of articles or materials to be packaged and operating to control, or stop, the feed of articles or material to be packaged
B65B 57/18 - Automatic control, checking, warning or safety devices causing operation of audible or visible alarm signals
B65B 61/06 - Auxiliary devices, not otherwise provided for, for operating on sheets, blanks, webs, binding material, containers or packages for severing webs, or for separating joined packages by cutting
99.
METHODS OF TREATING PROSTATE CANCER WITH GnRH ANTAGONIST
The invention provides methods and dosing regimens for safely and effectively treating androgen-dependent prostate cancer with a gonadotrophin releasing hormone (GnRH) antagonist without causing a testosterone spike and/or other side effect of GnRH agonist therapy such as a urinary tract infection, or an arthralgia-related or cardiovascular side effect.
36 - Financial, insurance and real estate services
Goods & Services
(1) Investment of funds; Providing monetary grants in the field of corporate, social responsibility, educational activities; providing monetary grants in the field of education and educational materials; providing monetary grants for events and activities, namely, scientific and professional meetings, community health fairs and health screening programs; capital investment; financial management; financial valuation of intellectual property assets; financial research services; financial investment analysis and research; financial sponsorship of medical research
